| Little Green Pharma Ltd (LGP) ORDINARY FULLY PAID |
Health Care |
$56 |
Application for quotation of securities - LGP
|
1 Sep 2025 9:21AM |
$0.123 |
$0.068 |
fallen by
44.49%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$94 |
LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study
|
1 Sep 2025 9:21AM |
$0.125 |
$0.100 |
fallen by
20%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Lumos Diagnostics Holdings Ltd (ASX: LDX) is collaborating with the Biomedical Advanced Research and Development Authority (BARDA).
- The partnership is to undertake a new US$6.2 million FebriDx paediatric study.
- The study will evaluate the use of FebriDx in CLIA-waived settings for children aged 2-12 years.
- Currently, FebriDx is FDA 510(k)-cleared for patients aged 12-64 years.
- The study aims to expand FebriDx use to more clinical sites, potentially increasing the addressable market 15-fold to over US$1 billion.
- The first enrolment for the study is expected in Q3 CY2025, targeting completion within a 12-month respiratory season.
- Milestones for the study include clinical trial setup, patient recruitment, and regulatory submissions.
- The study is supported by a non-dilutive funding package from BARDA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$94 |
LDX & BARDA partner on new US$6.2m FebriDx Paediatric Study
|
1 Sep 2025 9:21AM |
$0.125 |
$0.100 |
fallen by
20%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Lumos to commence FebriDx® pediatric study for ages 2–12 in CLIA-waived settings.
- BARDA supports study with US$6.198 million non-dilutive funding.
- Study expected to start in Q3 CY2025 during the 2025/26 U.S. respiratory season.
- Currently, FebriDx® is FDA 510(k)-cleared for ages 12–64.
- CLIA waiver could expand market access 15-fold to over US$1 billion.
- Potential access to 270,000 clinical sites, up from 18,000.
- Milestone payments from BARDA triggered by achieving 12 events.
- Study aims to differentiate between bacterial and non-bacterial respiratory infections.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Canyon Resources Ltd (CAY) ORDINARY FULLY PAID |
Materials |
$101 |
Definitive Feasibility Study Results and Reserves Upgrade
|
1 Sep 2025 9:20AM |
$0.265 |
$0.049 |
fallen by
81.51%
|
|
CAY - Price-sensitive ASX Announcement
Full Release
Key Points
- 33% increase in Ore Reserves to 144Mt at 51.2% Al2O3 and 1.7% SiO2
- First ore production planned for Q1 2026 with initial shipments in H1 2026
- Stage 1 CAPEX of US$96M supported by AFG Bank Cambank debt facility
- Project NPV of US$835M and IRR of 29%
- Staged development strategy to optimize capital expenditure
- High alumina grade bauxite expected to command a price premium
- Existing rail capacity and strategic Camrail investment support development
- Production targets include reaching 10Mtpa by Year 6
- Ore Reserves reported in accordance with JORC Code 2012
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MYECO Group Ltd (MCO) ORDINARY FULLY PAID |
Materials |
$13 |
Notification of cessation of securities - MCO
|
1 Sep 2025 9:19AM |
$0.015 |
$0.022 |
risen by
46.67%
|
|
| Mirrabooka Investments Limited (MIR) ORDINARY FULLY PAID |
Financials |
$578 |
Weekly Estimated NTA as at 29 August 2025
|
1 Sep 2025 9:19AM |
$3.410 |
$2.570 |
fallen by
24.63%
|
|
| Equigold NL (EQI) ORDINARY FULLY PAID |
Materials |
- |
IML EQIN TMD
|
1 Sep 2025 9:19AM |
$4.020 |
$4.020 |
fallen by
0%
|
|
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$706 |
Submission of FDA 510(k) Approval for Vision-MR Diagnostic
|
1 Sep 2025 9:19AM |
$1.405 |
$1.970 |
risen by
40.21%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor submitted Vision-MR Diagnostic Catheter for FDA 510(k) approval.
- Part of a strategy to enhance MRI-compatible electrophysiology (EP) devices.
- Follows the submission of NorthStar 3D Mapping System for FDA review.
- Goals include a fully integrated, radiation-free iCMR platform for the U.S.
- Imricor is a pioneer in MRI-compatible cardiac ablation products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$706 |
Submission of FDA 510(k) Approval for Vision-MR Diagnostic
|
1 Sep 2025 9:19AM |
$1.405 |
$1.970 |
risen by
40.21%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Submission of Vision-MR Diagnostic Catheter for FDA 510(k) approval.
- Device designed for real-time MRI guidance.
- Part of a full suite of MRI-compatible electrophysiology devices.
- Follows submission of NorthStar 3D Mapping and Guidance System.
- Aims to transform cardiac ablation by removing radiation.
- Imricor seeks to expand market presence with regulatory approvals.
- Utilizing MRI's superior imaging to improve interventional procedures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NGE Capital Limited (NGE) ORDINARY FULLY PAID |
Financials |
$44 |
Changes relating to buy-back - Appendix 3D
|
1 Sep 2025 9:19AM |
$1.220 |
$1.315 |
risen by
7.79%
|
|
| Horizon Gold Limited (HRN) ORDINARY FULLY PAID |
Materials |
$223 |
Entitlement Issue Shortfall Placement
|
1 Sep 2025 9:18AM |
$0.510 |
$1.145 |
risen by
124.51%
|
|
HRN - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful placement of entitlement issue shortfall.
- Raised $999,952 through 2,083,234 shares at $0.48 each.
- Total of $6,952,274 raised in the entitlement issue.
- Settlement and issuance scheduled for early September 2025.
- Company focuses on Gum Creek Gold Project in Western Australia.
- Mineral Resource Estimate at Gum Creek: 2.14 million ounces of gold.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Equigold NL (EQI) ORDINARY FULLY PAID |
Materials |
- |
IML EQIN PDS
|
1 Sep 2025 9:18AM |
$4.020 |
$4.020 |
fallen by
0%
|
|
| Horizon Gold Limited (HRN) ORDINARY FULLY PAID |
Materials |
$223 |
Entitlement Issue Shortfall Placement
|
1 Sep 2025 9:18AM |
$0.510 |
$1.145 |
risen by
124.51%
|
|
HRN - Price-sensitive ASX Announcement
Full Release
Key Points
- Horizon Gold Limited has received firm commitments for the placement of the entire shortfall of its entitlement issue.
- The placement involves 2,083,234 shortfall shares at $0.48 per share, raising $999,952.
- Settlement of these shares will occur on 3 September 2025, with the issuance on 4 September 2025.
- A total of $6,952,274 was raised from the renounceable entitlement issue announced on 21 July 2025.
- Post-allotment, the company will have 169,643,827 shares on issue.
- An Appendix 2A and a s708A(5)(e) Cleansing Notice will be issued after the shortfall shares are released.
- Horizon Gold Limited is focused on its 100% owned Gum Creek Project in Western Australia.
- The Gum Creek Project contains a Mineral Resource Estimate of 44.45Mt @ 1.50g/t Au for 2.14 million ounces of gold.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Blaze Minerals Limited (BLZ) ORDINARY FULLY PAID |
Energy |
$3 |
Loulombo Project Update
|
1 Sep 2025 9:18AM |
$0.003 |
$0.001 |
fallen by
66.67%
|
|
| Adriatic Metals Plc (ADT) ORDINARY FULLY PAID |
Materials |
- |
Scheme of Arrangement Update
|
1 Sep 2025 9:17AM |
$6.220 |
$6.220 |
fallen by
0%
|
|
| Tamboran Resources Corporation (TBN) CDI 200:1 US PERSON PROHIBITED EXCLUDING QIB |
Energy |
$363 |
Tamboran Resources Site Tour Presentation
|
1 Sep 2025 9:17AM |
$0.165 |
$0.265 |
risen by
60.61%
|
|
TBN - Price-sensitive ASX Announcement
Full Release
Key Points
- Tamboran Resources is progressing with a strategic development plan in the Beetaloo Basin, Australia.
- The company is working on multiple phases of gas projects, targeting the Northern Territory, East Coast, and LNG export markets.
- Tamboran holds a significant acreage position in the Beetaloo Basin, comparable to leading U.S. gas producers.
- There is a focus on developing infrastructure such as the Sturt Plateau Compression Facility and Pipeline, with completion expected by mid-2026.
- Tamboran has signed agreements with the Northern Territory Government and Native Title Holders to secure gas sales and benefit local communities.
- The company is planning to reduce costs and increase efficiency by using advanced drilling technology and local resources.
- Tamboran has secured strategic partnerships to accelerate its projects, including alliances with major energy companies like bp and Shell.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Little Green Pharma Ltd (LGP) ORDINARY FULLY PAID |
Health Care |
$56 |
Notification regarding unquoted securities - LGP
|
1 Sep 2025 9:17AM |
$0.123 |
$0.068 |
fallen by
44.49%
|
|
| Tamboran Resources Corporation (TBN) CDI 200:1 US PERSON PROHIBITED EXCLUDING QIB |
Energy |
$363 |
Tamboran Resources Site Tour Presentation
|
1 Sep 2025 9:17AM |
$0.165 |
$0.265 |
risen by
60.61%
|
|
TBN - Price-sensitive ASX Announcement
Full Release
Key Points
- Tamboran holds ~1.9 million net prospective acres in Beetaloo Basin.
- Focused on developing Beetaloo Basin shale gas resources.
- Progressing farmout in Phase 2 Development Area.
- Plan to reduce well costs by 40%.
- Secured agreements to supply gas to NT and East Coast markets.
- Enhancing operations with US technology.
- Strong community engagement and support for Indigenous businesses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Warriedar Resources Limited (WA8) ORDINARY FULLY PAID |
Materials |
- |
Waiver of ASX Listing Rule 6.23.2
|
1 Sep 2025 9:17AM |
$0.160 |
$0.265 |
risen by
65.63%
|
|
| Zeotech Limited (ZEO) ORDINARY FULLY PAID |
Materials |
$167 |
Large-Scale Commercial Auspozz Concrete Demonstration Pour
|
1 Sep 2025 9:16AM |
$0.080 |
$0.081 |
risen by
1.25%
|
|
ZEO - Price-sensitive ASX Announcement
Full Release
Key Points
- Zeotech completed its largest commercial-scale concrete pour with AusPozz™.
- The trial validated AusPozz™ as a high-performance supplementary cementitious material.
- The demonstration involved over 100 cubic metres of concrete and 17 truckloads.
- AusPozz™ can significantly reduce total binder and embodied carbon of concrete.
- The event attracted more than 35 stakeholders, including leading construction companies.
- The trial generated new commercial opportunities, including larger trials and potential MOUs.
- Feedback confirmed the product's integration into existing concrete supply chains and systems.
- AusPozz™ supports carbon reduction targets for 2030 and 2050.
- Zeotech plans further trials and commercial pathways for Auspozz™ adoption.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zeotech Limited (ZEO) ORDINARY FULLY PAID |
Materials |
$167 |
Large-Scale Commercial Auspozz Concrete Demonstration Pour
|
1 Sep 2025 9:16AM |
$0.080 |
$0.081 |
risen by
1.25%
|
|
ZEO - Price-sensitive ASX Announcement
Full Release
Key Points
- Zeotech Limited completed a large-scale commercial demonstration pour using their AusPozz™ product.
- The demonstration pour used approximately 100 cubic metres of concrete and 8 tonnes of AusPozz™.
- AusPozz™ is a low-carbon, high-reactivity metakaolin that serves as a supplementary cementitious material.
- The demonstration confirmed AusPozz™ can integrate into existing concrete supply chains and systems.
- AusPozz™ can reduce both the total binder and embodied carbon of concrete.
- The event attracted over 35 stakeholders from the construction and materials sectors.
- Positive feedback was received regarding the ease of placement and handling of AusPozz™.
- The demonstration has generated new commercial opportunities, including a 200m³ trial and a windfarm mix design.
- AusPozz™ is recognized as a key enabler of carbon reduction targets in the industry.
- Zeotech aims to contribute to the decarbonisation of the built environment through AusPozz™.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lode Resources Ltd (LDR) ORDINARY FULLY PAID |
Materials |
$21 |
Lode Divest Webbs Consol Silver Project
|
1 Sep 2025 9:16AM |
$0.150 |
$0.105 |
fallen by
30%
|
|
LDR - Price-sensitive ASX Announcement
Full Release
Key Points
- Lode Resources divests Webbs Consol to Rapid Critical Metals.
- Lode receives AUD 3.75 million and 115 million Rapid shares.
- Lode retains a 2% NSR royalty on Webbs Consol.
- Transaction strengthens Lode's balance sheet for exploration.
- Focus on consolidating silver assets in New South Wales.
- Deal subject to due diligence and shareholder approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aspen Group (APZ) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,168 |
Cleansing Notice
|
1 Sep 2025 9:16AM |
$4.340 |
$5.130 |
risen by
18.20%
|
|
| Rapid Critical Metals Limited (RCM) ORDINARY FULLY PAID |
Materials |
$42 |
RCM to Acquire Webbs Consol Silver Project from Lode Res.
|
1 Sep 2025 9:16AM |
$0.031 |
$0.035 |
risen by
12.90%
|
|
RCM - Price-sensitive ASX Announcement
Full Release
Key Points
- Rapid Critical Metals Limited to acquire 100% of the Webbs Consol Silver Project
- Total consideration: A$3.75 million and 115 million RCM shares, plus a 2% NSR royalty
- Acquisition strengthens RCM's position in New South Wales high-grade silver belt
- Comes amid strong silver prices, enhancing growth potential
- Subject to usual due diligence and RCM shareholder approval
- Expected to accelerate exploration and development activities
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rapid Critical Metals Limited (RCM) ORDINARY FULLY PAID |
Materials |
$42 |
RCM to Acquire Webbs Consol Silver Project from Lode Res.
|
1 Sep 2025 9:16AM |
$0.031 |
$0.035 |
risen by
12.90%
|
|
RCM - Price-sensitive ASX Announcement
Full Release
Key Points
- Rapid Critical Metals Limited to acquire Webbs Consol Silver Project.
- The acquisition complements RCM's existing assets, enhancing its silver and critical mineral portfolio.
- The Webbs Consol Silver Project is located in New South Wales, Australia.
- The acquisition is part of RCM's strategy to expand its asset base in Tier-1 jurisdictions.
- Improved silver prices and advanced geological insights will be leveraged for exploration and production.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
